Contrary to some previous findings, inhaled nitric oxide therapy does not reduce the risk of death or further lung problems in premature infants weighing less than 1,500 g and should not be administered to this population, according to a study by the National Institute of Child Health and Human Development of the National Institutes of Health. However, a separate prospective, longitudinal study of similarly sick and premature infants found that those treated with nitric oxide at birth had improved neurodevelopmental outcomes at 2 years of age.
Contrary to some previous findings, inhaled nitric oxide therapy does not reduce the risk of death or further lung problems in premature infants weighing less than 1,500 g and should not be administered to this population, according to a study by the National Institute of Child Health and Human Development of the National Institutes of Health. However, a separate prospective, longitudinal study of similarly sick and premature infants found that those treated with nitric oxide at birth had improved neurodevelopmental outcomes at 2 years of age.
The study by the NIH enrolled 420 infants born at less than 34 weeks' gestation weighing between 401 and 1,500 g. All of the infants had either respiratory distress syndrome, sepsis, pneumonia, or another severe breathing problem that required them to receive assisted ventilation. The infants were randomized to receive either placebo or 5 to 10 ppm inhaled nitric oxide.
The rate of death or bronchopulmonary dysplasia was 80% in the nitric oxide group versus 82% in the placebo group (relative risk [RR], 0.97; 95% CI; 0.86–1.06, P=0.52), and the rate of bronchopulmonary dysplasia was 60% versus 68% (RR 0.90; 95% CI; 0.75–1.08; P=0.26). The researchers found no significant differences in the rates of severe intracranial hemorrhage or periventricular leukomalacia either.
The second study included 138 children. The researchers found that about one quarter (24%) of the children that received NO therapy at birth had abnormal neurodevelopmental outcomes versus almost half (46%) of those who did not. Abnormal developmental outcomes were defined as either disability (cerebral palsy, bilateral blindness, or bilateral hearing loss) or delay (no disability, but one score of less than 70 on the Bayley Scales of Infant Development II). The improved outcomes in the NO group were primarily due to a 47% decrease in the risk of cognitive impairment (defined as a score of less than 70 on the Bayley Mental Developmental Index).
Van Meurs KP, Wright LL, Ehrenkranz RA, et al. Inhaled nitric oxide for premature infants with severe respiratory failure. N Engl J Med. 2005;353:13-22.
Mestan KK, Marks JD, Hecox K, et al. Neurodevelopmental outcomes of premature infants treated with inhaled nitric oxide. N Engl J Med. 2005;353:23-32.
Cesarean delivery reduces mortality risk in preterm breech births
December 2nd 2024In a recent study, infants born very preterm or extremely preterm had reduced odds of mortality when cesarean delivery was chosen as the mode of delivery, without a notable increase in any morbidity risk.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More
Major congenital malformations not linked to first trimester tetracycline use
November 20th 2024A large population-based study found that first-trimester tetracycline exposure does not elevate the risk of major congenital malformations, though specific risks for nervous system and eye anomalies warrant further research.
Read More
No link found between prenatal cannabis use and childhood developmental delay
November 5th 2024In a recent study, offspring of women with cannabis use in early pregnancy confirmed by self-report or toxicology test were not at an increased risk of childhood early developmental delay up to the age of 5.5 years.
Read More
Prenatal cannabis use not linked to offspring ASD development
November 1st 2024In a recent study, adjustments for maternal characteristics mediated the association between maternal prenatal cannabis use and offspring autism spectrum disorder, indicating no statistically significant increase in risk.
Read More